Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.
Charles Heise, Associate Director, Bioprocess Strategy & Development, FUJIFILM Biotechnologies
Advertisement
Articles by Charles Heise, Associate Director, Bioprocess Strategy & Development, FUJIFILM Biotechnologies
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
EU Clears Subcutaneous Biologic for Lupus, Advancing Patient-Controlled Delivery
2
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
Developing Next-Gen Cell Lines Using Targeted Integration
5